학술논문
Phase 2 Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Following Second-Line Lenalidomide (LEN)-Based Treatment (Tx) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): An Updated Analysis of Efficacy and Safety
Document Type
Abstract
Author
Source
In Clinical Lymphoma Myeloma and Leukemia February 2017 17(1) Supplement:e141-e141
Subject
Language
ISSN
2152-2650